case_images: PMC10962458_01
case_images: Chest computed tomography. (A-C) Chest computed tomography (CT) on admission showing massive consolidation in the left lower lung field and left-sided pleural effusion. (D-F) Chest CT after 1 week of treatment with moxifloxacin, showing a reduction in the consolidation, lung lesions, and pleural infusion. (G-I) Chest CT after 2 weeks of treatment with moxifloxacin.
case_images: IMCRJ-17-187-g0001.jpg
case_images: PMC10962458_01_IMCRJ-17-187-g0001.jpg
case_images: f0001
case_images: Chest computed tomography (CT) on day 1 after admission revealed massive consolidation in the left lower lung and a left-sided pleural effusion (Figure 1), leading to a diagnosis of pneumonia. Repeat chest CT 1 week after starting MFX showed a reduction in the size of the lung lesions (Figure 1). Follow-up chest CT showed a marked reduction in the size of the lung lesions (Figure 1), and SARS-CoV-2 nucleic acid testing of an NPS was negative.
case_images: Detection depths and coverage of SARS-CoV-2 Omicron XBB.1 and Chlamydia psittaci in different sample types. (A and B) Detection depths and coverage of SARS-CoV-2 Omicron XBB.1 in (A) BALF and (B) nasopharyngeal swab specimens. (C and D) Detection depths and coverage of C. psittaci in (C) BALF and (D) nasopharyngeal swab specimens.
case_images: IMCRJ-17-187-g0002.jpg
case_images: PMC10962458_01_IMCRJ-17-187-g0002.jpg
case_images: f0002
case_images: TIANamp Micro DNA Kit (DP316, Tiangen Biotech Co., Beijing, China), followed by DNA/RNA library construction, high-quality sequencing, and classification analysis, as described previously. The mNGS analysis detected C. psittaci in the BALF (sequence number: 874), peripheral blood (sequence number: 2), and NPS (sequence number: 4) samples, as well as SARS-CoV-2 Omicron XBB.1 in the BALF (sequence number: 1,847,027) and NPS (sequence number: 224,671) samples (Figure 2). 
case_images: The patient's clinical course and treatment. Body temperature alterations and antibacterial therapy, (i) 4.5 g piperacillin-tazobactam administered as an intravenous bolus every 8 hours on days 1-3 and (ii) 0.4 g of moxifloxacin administered as an intravenous bolus once daily on days 4-11.
case_images: IMCRJ-17-187-g0003.jpg
case_images: PMC10962458_01_IMCRJ-17-187-g0003.jpg
case_images: f0003
case_images: The antibiotic therapy was switched to intravenous moxifloxacin (MFX) (400 mg daily), and 2 days later, the fever resolved (Figure 3).